CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Valo Therapeutics is developing PeptiCHIP, a microfluidic device designed to identify specific cancer-related antigens that can enhance immunotherapy effectiveness. This technology aims to streamline the process of antigen identification, making it faster and more efficient for clinical applications.
Clinical translation of cancer immunotherapies remains very challenging since 60-80% of patients fail to respond.The challenge stands in identifying specific tumour-fingerprints – the neoantigens - that are peptides expressed uniquely by cancer cells and that are capable of triggering an efficient immune response against cancer.
Currently there is no standard method to identify antigens and the few methods available have significant limitations by being quite long, complicated and resource deman…
VALO THERAPEUTICS OY
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
